Human Microbiome Therapeutics Market Size, Emerging Technologies, Future TrendsPosted by topindustryreports@gmail.com on December 23rd, 2020 The report offers a comprehensive analysis of the competitive landscape of the market through extensive profiling of the key competitors. The section on the competitive analysis covers product portfolio, company overview, production and manufacturing capacity, financial standing, revenue and gross profit margins, and market position. It also sheds light on the mergers and acquisitions, joint ventures, collaborations, and partnerships occurring in the market. However, the surging costs of equipment and infrastructure, as well as challenging laboratory bacteria development & isolation procedures, are predicted to restrain market growth in the following years. For industry-leading market insights, visit the link below: https://www.emergenresearch.com/industry-report/human-microbiome-therapeutics-market The Global Human Microbiome Therapeutics Market is estimated to garner a valuation of USD 1,098.4 Million by 2027, according to the latest assessment by Emergen Research. The industry is speculated to grow substantially with the rising prominence of the market in the sphere of personalized medicine & nutrition. Moreover, technological improvements in the metagenomics sector and the therapeutic system would also impel market growth in the forecast duration.
o Prescription Drugs o Medical Foods o Probiotics o Prebiotics
o Microbial Consortia o Small Molecule Therapies o Phage Cocktail o Genetically Modified Single Strain Bacteria o Microbial Ecosystems o Single Strain Whole Bacteria
o Oncology o Dermatological Disorders o Autoimmune Disorders o Infectious Disease o Metabolic Disorders o Others
o Irritable Bowel Syndrome o Crohn’s Disease o Diabetes o difficile o Others Emergen Research has categorized the Global Human Microbiome Therapeutics Market based on product, approach, therapeutic area, disease, and region: Key Highlights From The Report The infectious disease sub-segment is predicted to lead the therapeutic area segment in the forecast years owing to the increasing prevalence of microbial dysbiosis-based diseases and the increasing usage of antibiotics and drug development for the purposes of microbiome-based treatments. North America is predicted to dominate the overall market share with the rising consumption of dietary supplements in the region. Technologically specialized research establishments to facilitate the development of experimental therapeutics, escalating healthcare expenditure, and the increasing number of health-conscious consumers are assisting the growth of the regional market. Key participants include Oxidien Pharmaceuticals, LLC, DermBiont, Inc, LNC Therapeutics SA, Carbiotix AB, Embion Technologies SA, BiomX Ltd., CoreBiome, Inc., Biotagenics Inc., Commense Inc, and Finch Therapeutics, among others. Like it? Share it! More by this author |